# Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)

> **NCT06770270** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 68 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Pucotenlimab

## Key facts

- **NCT ID:** NCT06770270
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2030-06-30
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06770270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06770270, "Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06770270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*